Journal of Clinical Medicine Research

Objective: to investigate the clinical effect of lactase additive in the treatment of lactose intolerance (LI) in preterm infants. Methods: 100 cases of preterm infants with LI admitted to our hospital from August 2023 to June 2024 were selected and randomly divided into the control group (n = 50) and observation group (n = 50). The control group was treated with normal breast milk, and the observation group was treated with lactase additive on the basis of the control group. The clinical symptoms, developmental status, levels of nutrition adverse reactions of the children in the two groups were compared. RESULTS: After 2 weeks of treatment, the incidence of abdominal distension, diarrhea, and spitting up in the observation group was lower than that in the control group, and the increase in body mass, growth in length, and growth in head circumference was higher than that in the control group (P < 0.05). After 2 weeks of treatment, the serum calcium level of both groups was higher than that before treatment, and the serum AKP level was lower than that before treatment (P＜0.05). During the treatment period, no obvious adverse reactions occurred in both groups of children. CONCLUSION: Lactase additive is effective in the treatment of LI in preterm infants, which can significantly alleviate the clinical symptoms of lactose intolerance, promote their growth and development, and has a high level of safety, which is worthy of clinical popularization and application.